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thetical cohort of 1,000 PCI patients/year (STEMI= 6.4%, NSTEMI/UA= 16.7%, stable 
angina= 76.9%) treated with heparin+/-GPI (weighted average of 30.0% GPI use across 
diagnoses), use of bivalirudin+cangrelor+2.8% GPI provided a hospital $0.95MM in 
clinical value. Cost-offsets were derived from a reduction in GPI use, lower ischemic 
and bleeding events. Sensitivity was assessed in using heparin+/-GPI; GPI%= 70.6% 
(extreme from APEX-AMI trial) vs. bivalirudin+cangrelor+9.7% GPI where the clini-
cal value was estimated at $1.59MM. ConClusions: Use of bivalidudin+cangrelor 
during PCI delivers an estimated clinical value of at least $950 per PCI-patient, $1,590 
in STEMI patients with improved clinical outcomes.
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objeCtives: Complications like mechanical lead damage, major infections and 
hematomas during surgical replacement of pacemaker and implantable cardioverter 
defibrillator contribute to considerable additional costs for hospitals. This study 
aimed to evaluate the economic impact if the currently applied traditional surgical 
intervention (TSI) by using scissors, scalpels and electrocautery is replaced by a 
new and innovative surgical system, called PEAK PlasmaBladeTM (PPB). Methods: 
A retrospective analysis examined 508 patients with TSI and 84 patients with PPB, 
who underwent generator replacement at the general hospital in Linz, Austria. 
Intraoperative complications (lead damages, infections, hematomas) and duration 
of operating time for TSI and PPB were analyzed. Economic analysis included the 
costs for personnel, facility and consumables as well as the estimates for the budget 
impact. Results: Proportion of males (TSI = 59.4%; PPB = 63.1%) and mean age (TSI 
= 74.3±12.4, PPB = 74.2±12.9 years) were not significantly different between the two 
groups. The lead damage was significantly higher with TSI than with PPB (5.7% and 
0.0%; p= 0.024) and the operation time with TSI was significantly longer than with 
PPB (47.5±24.0 and 27.8±6.4 minutes; p< 0.0001). Other complications, like revisions 
of hematomas and infections (TSI = 1.6%; PPB = 2.4%), did not significantly differ 
between TSI and PPB. Reduced costs associated with operation room use, hospital 
staff and replacement of damaged leads resulted in a cost saving of € 124 per patient 
when using PPB instead of TSI. Based on estimated 2,600 patients annually under-
going generator replacement in Austria, the use of PPB may result in cost savings 
of € 321,000. ConClusions: PEAK PlasmaBladeTM has the potential to minimize 
the risk of lead damage while decreasing surgery time, resulting in a more efficient 
utilization of the operation room. Along with cost savings and improved quality of 
care hospitals may increase the number of daily surgeries.
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objeCtives: The objective of this analysis is to examine the impact of the new ACC/
AHA clinical practice guideline on pharmacy utilization of cholesterol drugs in a 
managed care setting. Methods: Pharmacy claims from a national PBM over a one 
year period were used to project the number of potential members who will be start-
ing or switching statin therapies. Potential members include members with diabetes 
or hypertension between 40-75 years of age and not on any cholesterol medications 
as well as members receiving lower-intensity statins or other non-statin cholesterol 
therapies. The current cholesterol market share was used to project pharmacy uti-
lization for potential members that will be starting or switching therapies. Expert 
opinion was used in areas where information was not available in the medical 
literature. Results: An estimated 11-19% of commercial and 38-45% of Medicare 
members not receiving any cholesterol agents may be potentially started on statin 
therapies. These new starts, along with the other members who may be switching 
from non-statin cholesterol agents or increasing their statin dosages, will be pro-
jected to increase the number of statin prescriptions approximately 75-80% in the 
commercial and 32-34% in the Medicare population. On the other hand, the number 
of non-statin cholesterol prescriptions is anticipated to decrease 47-67% and 70% 
in the commercial and Medicare population, respectively. ConClusions: The new 
cholesterol guideline is projected to have a huge impact on cholesterol drug utili-
zation.  Estimates are highly dependent on expert opinions and further statistical 
inference models will be applied in future studies to examine these uncertainties.
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objeCtives: This post-hoc analysis estimated comorbidity costs over 2 years with 
PHEN/TPM ER 7.5/46 mg compared with lifestyle modification (LM) alone for weight 
management in an overweight/obese population. Methods: A 2-year model was 
developed from a health plan perspective estimating comorbidity cost offsets for 
a reduction in body mass index (BMI) and comorbidity costs for incident cases 
of hypertension, type 2 diabetes mellitus (T2DM), and dyslipidemia. BMI changes 
over 2 years were from SEQUEL, a 52-week extension study of CONQUER, a phase 
3, 56-week trial that randomized patients to PHEN/TPM ER or placebo (all patients 
received LM). Cost offsets for BMI reduction were calculated by multiplying changes 
in BMI by the medical ($164) and pharmacy ($113) cost change per unit of BMI 
(Wang 2006). Incident comorbidity costs were based on patients who progressed 
from no medication use at baseline to use of ≥ 1 medication at endpoint of SEQUEL 
(Garvey 2012). Literature-based cost estimates of the annual cost of treating each 
comorbidity were applied to the rates of disease progression to calculate costs. The 
cost of PHEN/TPM ER was not included in the analysis. Results: BMI reductions 
over 2 years were 3.64kg/m2 for PHEN/TPM ER 7.5/46 and 0.24kg/m2 for LM, trans-
lating to cost offsets of $1008 and $67, respectively. Rates of progression to hyper-
tension (15.8% vs 18.7%), T2DM (2.3% vs 5.6%), and dyslipidemia (12.8% vs 24.0%) 
were lower for PHEN/TPM ER 7.5/46 compared with LM, respectively. Assuming 1% 
market uptake of PHEN/TPM ER 7.5/46 over 2 years, the savings due to BMI-related 
comorbidity cost offsets is $2,769,763 or $0.12 per member per month (PMPM) and 
reduced progression to comorbidities is $1,794,703 or $0.07 PMPM. ConClusions: 
Treatment with PHEN/TPM ER 7.5/46 may be associated with comorbidity cost sav-
ings due to cost offsets for BMI reduction and reduced progression to comorbidities.
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objeCtives: Incremental improvements are inherent in medical devices; many of 
these can offer significant financial benefits which, ultimately, improve the cost-
effectiveness of already established technologies. Biventricular pacing, commonly 
combined with a defibrillator (“Cardiac Resynchronization Therapy – Defibrillator” 
or CRT-D), has been widely used in patients with Heart Failure (HF) to increase 
survival, improve QoL, and reduce HF hospitalizations. Nevertheless, traditional 
CRT-D devices require periodic manual reprogramming (a.k.a. “optimization”) 
guided by echocardiography. Newer devices equipped with innovative algorithms 
(AdaptivCRT™, Medtronic, MN, USA) monitor heart electrical activity and auto-
matically reprogram the device once-per-minute. In addition to eliminating the 
manual process, AdaptivCRT™ appeared to positively impact patient allocation to 
functional classes (as defined by the New York Heart Association – NYHA) against 
traditional echo-based device optimization. We investigated the financial impli-
cations of AdaptivCRT™ in Japan. Methods: We conducted a Cost-Minimization 
Analysis (CMA), comparing AdaptivCRT™ with traditional optimization, using 
Markov processes. Patients progress from early-stage NYHA classes to more 
advanced disease, or death. The initial allocation of patients to the classes and the 
transition probabilities were based on the aCRT RCT. Each NYHA class is associated 
with higher levels of costs. We used the Japanese fee schedule, local HF treatment 
guidelines and prescription drug labelling to assess resource utilization within each 
class. Results: Assuming 3,200 patients (the approximate number of Japanese 
CRT-D patients per annum), our model predicts overall cohort costs (excluding 
initial implant costs) of ¥16,545M (USD$165M) with AdaptivCRT™ and ¥17,809M 
(USD$178M) without. This equates to savings of approximately USD$13M overall, 
or USD$4,000 per patient. ConClusions: AdaptivCRT™ use appears associated 
with significant cost-offsets driven by superior outcomes. This demonstrates that 
incremental device therapy improvements can provide clinical and economic value. 
Further research should examine AdaptivCRT™ impact on health care utility and 
improvement in the overall cost-effectiveness of CRT-Ds.
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objeCtives: Develop a probabilistic and comparative cost analysis, from patient 
and hospital perspective of Remote vs. In-Office monitoring in patients with car-
diac rhythm devices. Methods: An economic interactive probabilistic cost model 
was built in excel. The cost variables were identified with patient and hospital 
KOL surveys regarding timing and cost related issues. Secondary data from a 2012 
Heart Rhythm Society study was used. Medical outpatient direct costs were taken 
from the Clinic. Uncertainty adjustment was made to probabilistic variables. Beta, 
normal and Gamma distributions were used for probabilistic, time and cost vari-
ables. Min and max ranges were used when standard deviations were no available. 
After deterministic results, Monte Carlo simulation with 1000 iterations was done. 
The main statistic results obtained were deterministic and probabilistic average 
with their corresponding confident intervals, probabilistic density function and 
cumulative density function. Results: Probabilistic patient total average costs for 
Remote monitoring was US$18.5 (95% CI US$2.0 – US$152.6) in contrast to In-office 
monitoring with US$ 51.41 (95% CI US$ 5.0 – 386.7 US$), which represents a 64% 
cost reduction and a narrow confident interval. Probabilistic outpatient hospital 
total average cost for Remote monitoring was US$33.1 (95% CI US$31 – US$35.2) in 
contrast to In-Office monitoring with US$ 63.9 (95% CI US$ 59.3 –US$68.8), which 
represents a 48% cost reduction and a narrow confident interval. In the cumulative 
distribution function for total patient cost and for total outpatient hospital cost, 
the probability for Remote monitoring to have a lower cost than each considered 
threshold was higher than In-Office interrogation for all values. ConClusions: 
This cost model allows comparing the probabilistic cost distribution of the Remote 
vs. In-Office Interrogation cardiac rhythm devices. The Remote monitoring costs 
are lower for the patient and for the ambulatory hospital services and are more 
predictable than In-Office interrogation costs.
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objeCtives: To estimate total costs and resource use of acute hospital care in 
a sample of patients with large vessel ischemic stroke treated at our University 
Hospital, comparing those with and without non-valvular atrial fibrillation 
